Table 2.
Incidence Rates of New AIDS-defining Events in Patients with Immune Response (CD4+ Cell Count ≥200 cells/μL) and Immuno-virological Discordance (Failure to Achieve CD4+ Cell Count ≥200 cells/μL)
| Immune response |
Immuno-virological discordance |
|||||||||
| IR per 1000 PYFU |
IR per 1000 PYFU |
|||||||||
| Duration of viral suppression | PYFU | AIDS-defining events | IR | 95% CI | PYFU | AIDS-defining events | IR | 95% CI | ||
| 1 Year | 673 | 11 | 16.3 | 8.2 | 29.2 | 408.4 | 18 | 44.1 | 26.1 | 69.7 |
| 0–6 Months | 326 | 8 | 20.6 | 8.9 | 40.7 | 272.4 | 15 | 55.1 | 30.8 | 90.8 |
| 7–12 Months | 347 | 3 | 8.0 | 1.6 | 23.2 | 136.0 | 3 | 22.1 | 4.6 | 64.5 |
| 2 Years | 637 | 7 | 11.0 | 4.4 | 22.6 | 113.9 | 2 | 17.6 | 2.1 | 63.4 |
| 3 Years | 429 | 1 | 2.3 | 0.1 | 13.0 | 38.7 | 0 | 0 | 0 | 95.3 |
| 4 Yearsa | 414 | 2 | 4.8 | 0.6 | 17.4 | 22.3 | 0 | 0 | 0 | 165.5 |
NOTE. ART, antiretroviral therapy; CI, confidence interval; IR, incidence rate; PYFU, person-year of follow-up.
a
In patients with immune response, 1 AIDS-defining event (recurrent esophageal candidiasis) occurred at month 73.